Living Drugs that Fight Cancer

Although the process collects patients’ own white blood cells, they must still undergo a mild chemotherapy to weaken their immune systems — known as conditioning — to prevent their immune systems from turning against these modified reinforcements.

“Once injected, these CAR-T cells are exposed to the cancer cells, multiply in the body and attack the cancer cells directly, causing killing until there is no more cancer in the body,” Cingam said.

The immune response kicks in right away, he said. But the entire process can take a bit longer.

“Anywhere between one and seven days is when it’s in its full-blown effect,” Cingam said.

As with any immune response, patients will experience side effects, and in this case, they must be strictly monitored.

“These are living drugs,” Cingam said. “Once in your body, they’re not going to take effect and leave. They are multiplying in your body, releasing inflammatory cytokines, which can cause high-grade fevers, or we can see inflammation in or around the brain. So, we give steroids and other anti-inflammatory therapies to limit this inflammation.”

Patients must be watched closely after the procedure, which requires a major time commitment. Right now, New Mexico patients undergoing CAR-T must travel hundreds of miles for treatment, and that means a month-long stay or more out of the state.

“This [therapy] requires patients to spend at least four weeks near the facility,” Cingam said. “Out of those four, they may be admitted only one week. If you go [out of state], they might let you out [of the hospital], but you still have to stick around for another four weeks.”

Having the option of receiving CAR-T therapy in Albuquerque means less travel and fewer obstacles for patients and their loved ones in New Mexico. The UNM Cancer Center Bone Marrow Transplant and Cellular Therapy program currently offers four commercial CAR-T therapies to treat several types of lymphoma and multiple myeloma.

“We can now treat relapsed or refractory diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, multiple myeloma and acute lymphoblastic lymphoma,” said Cingam. “And, we’re planning to open CAR-T clinical trials in the spring.”

The CAR-T program is part of a broader roster of blood disorder treatments offered at the UNM Cancer Center. That roster includes autologous and allogeneic stem cell transplants and treatment for non-cancerous blood disorders. Cingam has helped the team add the different CAR-T therapies.

And as Cingam and other doctors and researchers around the country learn more about CAR T, it can be used earlier in the course of treatment and lead to better recovery for patients. The UNM Cancer Center has already opened its first CAR T clinical trial using a product that can simultaneously target two different molecules on the surface of cancer cells. Other CAR-T clinical trials are in process.

“CAR-T is much more effective compared to other treatments,” said Matthew Fero, MD, director of the Bone Marrow and Stem Cell Transplant Program at UNM Cancer Center. “It gives patients another great treatment option.”